Amniotic membrane for treating skin graft donor sites: A systematic review and meta-analysis.
To evaluate the efficacy and safety of amniotic membrane (AM) for the healing of split-thickness skin graft donor sites (STSGDS). Electronic search of PubMed, Cochrane library and EMBASE for randomized controlled trials (RCTs) or non-randomized clinical trials (NRCTs) of AM therapy in STSGDS. Review Manager5.3 was utilized to analyze and present the data. Seven studies with 219 patients were included. Compared with other treatments, the mean difference (MD) in healing time was -3.87 days (95% CI -4.39, -3.35; P < 0.00001); Relative risk for the healing rate was 1.61 (95% CI 0.0.47-5.47; P = 0.44); There was no statistical difference in the sensation of pain (P > 0.05); The relative risk for infection rate was 0.66 (95% CI 0.29, 2.18; I2 = 0%; P = 0.65). This systematic review and meta-analysis indicate that it is effective and safe to use AM for treating STSGDS.